Liposomal Amphotericin B (AmBisome) in the Treatment of Complicated Kala-Azar Under Field Conditions.

Hdl Handle:
http://hdl.handle.net/10144/17671
Title:
Liposomal Amphotericin B (AmBisome) in the Treatment of Complicated Kala-Azar Under Field Conditions.
Authors:
Seaman, J; Boer, C; Wilkinson, R; de Jong, J; de Wilde, E; Sondorp, H; Davidson, R N
Journal:
Clinical Infectious Diseases
Abstract:
An open trial of liposomal amphotericin B (AmBisome [L-AmB]; Vestar, San Dimas, CA) for treatment of complicated visceral leishmaniasis was performed in Sudan. Forty-nine patients were treated, and there were six deaths (12% mortality); these were not attributed to therapy. Thirty-seven patients were selected for the trial because of (1) relapse after treatment with a combination of pentavalent antimony (Sbv) and aminosidine, (2) incomplete parasitological response to Sbv and aminosidine, or (3) severe illness. Drug regimen 1 (3 doses of 3-5 mg/kg, on days 0, 3, and 10) cured 8 (50%) of 16 patients; regimen 2 (6 doses of 3-5 mg/kg, on days 0, 3, 6, 8, 10, and 13) cured 14 (88%) of 16. For four of 10 partial responders, "rescue" therapy with L-AmB alone (3 mg/kg daily for 10 days) resulted in cure. Twelve less-unwell patients received regimen 3 (4 doses of 4-5 mg/kg, on days 0, 2, 5, and 7); seven of 11 patients evaluated (64%) were cured. The optimal regimen of L-AmB in these circumstances is administration of 4 mg/kg on days 0, 3, 6, 8, 10, and 13.
Affiliation:
Medecins Sans Frontieres Holland, The Netherlands.
Publisher:
Published by: Infectious Diseases Society of America
Issue Date:
Jul-1995
URI:
http://hdl.handle.net/10144/17671
PubMed ID:
7578729
Additional Links:
http://www.journals.uchicago.edu/page/cid/brief.html
Language:
en
ISSN:
1058-4838
Appears in Collections:
Leishmaniasis/Kala Azar

Full metadata record

DC FieldValue Language
dc.contributor.authorSeaman, J-
dc.contributor.authorBoer, C-
dc.contributor.authorWilkinson, R-
dc.contributor.authorde Jong, J-
dc.contributor.authorde Wilde, E-
dc.contributor.authorSondorp, H-
dc.contributor.authorDavidson, R N-
dc.date.accessioned2008-02-07T12:08:56Z-
dc.date.available2008-02-07T12:08:56Z-
dc.date.issued1995-07-
dc.identifier.citationLiposomal Amphotericin B (AmBisome) in the Treatment of Complicated Kala-Azar Under Field Conditions. 1995, 21 (1):188-93 Clin. Infect. Dis.en
dc.identifier.issn1058-4838-
dc.identifier.pmid7578729-
dc.identifier.urihttp://hdl.handle.net/10144/17671-
dc.description.abstractAn open trial of liposomal amphotericin B (AmBisome [L-AmB]; Vestar, San Dimas, CA) for treatment of complicated visceral leishmaniasis was performed in Sudan. Forty-nine patients were treated, and there were six deaths (12% mortality); these were not attributed to therapy. Thirty-seven patients were selected for the trial because of (1) relapse after treatment with a combination of pentavalent antimony (Sbv) and aminosidine, (2) incomplete parasitological response to Sbv and aminosidine, or (3) severe illness. Drug regimen 1 (3 doses of 3-5 mg/kg, on days 0, 3, and 10) cured 8 (50%) of 16 patients; regimen 2 (6 doses of 3-5 mg/kg, on days 0, 3, 6, 8, 10, and 13) cured 14 (88%) of 16. For four of 10 partial responders, "rescue" therapy with L-AmB alone (3 mg/kg daily for 10 days) resulted in cure. Twelve less-unwell patients received regimen 3 (4 doses of 4-5 mg/kg, on days 0, 2, 5, and 7); seven of 11 patients evaluated (64%) were cured. The optimal regimen of L-AmB in these circumstances is administration of 4 mg/kg on days 0, 3, 6, 8, 10, and 13.en
dc.language.isoenen
dc.publisherPublished by: Infectious Diseases Society of America-
dc.relation.urlhttp://www.journals.uchicago.edu/page/cid/brief.html-
dc.rightsArchived on this site with permission and copyright by the Infectious Diseases Society of Americaen
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAmebicidesen
dc.subject.meshAmphotericin Ben
dc.subject.meshAnimalsen
dc.subject.meshAnti-Bacterial Agentsen
dc.subject.meshAntimonyen
dc.subject.meshChilden
dc.subject.meshChild, Preschoolen
dc.subject.meshDrug Administration Scheduleen
dc.subject.meshDrug Carriersen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshInfanten
dc.subject.meshLeishmania donovanien
dc.subject.meshLeishmania infantumen
dc.subject.meshLeishmaniasis, Visceralen
dc.subject.meshLiposomesen
dc.subject.meshLymph Nodesen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshParomomycinen
dc.subject.meshRecurrenceen
dc.subject.meshSpleenen
dc.subject.meshSudanen
dc.titleLiposomal Amphotericin B (AmBisome) in the Treatment of Complicated Kala-Azar Under Field Conditions.en
dc.contributor.departmentMedecins Sans Frontieres Holland, The Netherlands.en
dc.identifier.journalClinical Infectious Diseasesen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.